MedTrace Logo

A Study of DCC-2701 in Participants With Advanced Solid Tumors

NCT02228811 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-02-01

No results posted yet for this study

Summary

The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.

Conditions

  • Locally Advanced Tumors
  • Metastatic Solid Tumors
  • Cancers With MET Genomic Alterations
  • Cancers With TRK Genomic Alterations

Interventions

DRUG

DCC-2701 tablet

Sponsors & Collaborators

  • Deciphera Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Oliver Rosen, M.D. · Deciphera Pharmaceuticals, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-11-30
Completion
2018-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228811 on ClinicalTrials.gov